3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
9
Unknown
3
Terminated
2
Recruiting
2
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma
2
Hematologic Neoplasms
2
Subcutaneous panniculitis-like T-cell lymphoma
1
Sezary Syndrome
1
Recurrence
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Infectious Mononucleosis
1
Immunoblastic Lymphadenopathy
1
Hodgkin Disease
1
Enteropathy-Associated T-Cell Lymphoma
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
Brentuximab Vedotin
×
Clear all
NCT02780011
2018-07-27
AD3LE
The Methodist Hospital Research Institute
Phase 1
Withdrawn